Fig. 4.

Natural variation of wild-type viruses and BCO values. Fourteen wild-type subtype B and non-B HIV-1 isolates (A) (obtained from the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH) and 50 subtype B wild-type HIV-1 strains (B) (obtained from antiretroviral-naïve patients) were used to construct p2-INT-recombinant viruses, and their drug susceptibilities were quantified using the ViralARTS HIV assay. Three independent EC₅₀ replicates for each drug were used to calculate the fold changes (FC) of the different query viruses relative to the HIV-1_NL4-3hRluc control, and the mean EC₅₀ fold change is indicated. (C) Upper BCO values for each antiretroviral drug calculated as the 99th percentile of the FC distribution using ViralARTS HIV.